Currently, one of the 'hottest topics' in the GMP environment is the use of Artificial Intelligence (AI). Is it also possible to use AI in the field of equipment qualification? We already surveyed this in 2024. Now two years have passed. What has changed? What is the current view of the use of AI?
The European Medicines Agency (EMA) and the Coordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh) have revised Appendix 1 of their Questions and Answers document on nitrosamine impurities. Revision 14 adds Acceptable Intakes (AIs) for additional nitrosamines and other N-nitroso compounds.
The International Pharmaceutical Excipients Council (IPEC) published the third version of its Excipient Composition Guide for Pharmaceutical Excipients. The guide provides voluntary best-practice guidance to help manufacturers establish excipient composition profiles and communicate relevant information to users and regulators.
Not as the result of an inspection, but due to more than 95 incidents caused by a microbially contaminated sterile solution, the FDA issued a Warning Letter to a US-based veterinary manufacturer.
The European Medicines Agency (EMA) has published a "Draft reflection paper on the investigation of drug interactions of herbal medicinal products". Comments can be submitted until 15 January 2027.
The European Medicines Agency (EMA) has published version 3 of the User manual for the eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) user interface (XEVMPDweb).
The International Council for Harmonisation (ICH) has expanded its training library with new training materials for the ICH E6(R3) Good Clinical Practice (GCP) guideline. Read more in our news article.
On 14 October 2026, the European Medicines Agency (EMA) updated its information page "Investigation of bioequivalence - Scientific guideline". The update explains how new ICH guidelines affect the European regulatory framework. The guideline itself has not been changed.
The Swissmedic has been in direct discussions with industry associations regarding possible simplifications in the assessment of GMP compliance by foreign manufacturers and has clarified outstanding issues.
In a recent Warning Letter to a Chinese manufacturer of over-the-counter medicines that are also marketed in the USA, the FDA clarifies what it understands by "sterile".